United Therapeutics Corporation $UTHR Shares Purchased by M&T Bank Corp

M&T Bank Corp boosted its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 171.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 3,142 shares of the biotechnology company’s stock after buying an additional 1,985 shares during the quarter. M&T Bank Corp’s holdings in United Therapeutics were worth $1,531,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Abich Financial Wealth Management LLC acquired a new stake in shares of United Therapeutics in the third quarter valued at approximately $44,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Investors are focusing on United Therapeutics’ pipeline and growth catalysts, especially encouraging Tyvaso data in IPF and optimism around ralinepag’s blockbuster potential, which could support future revenue growth. UTHR Q1 Earnings Miss Estimates, Shares Jump on Strong Outlook
• Positive Sentiment: Royal Bank of Canada kept an outperform rating and only slightly lowered its price target to $701 from $707, signaling continued confidence in upside from current levels. RBC lowers price target on UTHR
• Neutral Sentiment: United Therapeutics held its Q1 2026 earnings call, which investors are likely parsing for commentary on Tyvaso, ralinepag, and the company’s growth outlook. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 results missed estimates, with EPS of $5.82 versus expectations of $7.00 and revenue of $781.5 million versus $797.4 million expected; revenue also declined 1.6% year over year. Q1 2026 Financial Results
• Negative Sentiment: Insider selling may be weighing on sentiment: CEO Martine Rothblatt sold 9,500 shares and EVP Paul Mahon sold 8,300 shares, both sizable reductions in their holdings. Rothblatt SEC filing Mahon SEC filing

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Oppenheimer increased their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $575.00 to $735.00 in a report on Thursday. HC Wainwright increased their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $564.94 on Friday. The stock has a fifty day moving average price of $550.17 and a 200 day moving average price of $501.37. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a market cap of $23.98 billion, a PE ratio of 20.85, a P/E/G ratio of 1.77 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. Analysts anticipate that United Therapeutics Corporation will post 27.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $589.52, for a total transaction of $5,600,440.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,883,223.76. This trade represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,890,130.68. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 485,155 shares of company stock valued at $266,370,949 in the last ninety days. Company insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.